Nieuws en video's - COLOPLAST A/S [CBOE]

H1 2023/24 Interim financial results, H1 2023/24 1 October 2023 - 31 March 2024 Coloplast delivered a solid Q2 with 8% organic growth and an EBIT margin 1) of 27%. Reported revenue in DKK grew 9% with 4%-points contribution from Kerecis (underlying growth of around 35%), partly offset by currencies. Organic growth rates by business area: Ostomy Care 7%, Continence Care 8%, Voice and Respiratory Care 13%, Advanced Wound Care 8% (Advanced Wound Dressings 8%) and Interventional Urology 5%....

Q1 2023/24 Interim financial results, Q1 2023/24 1 October 2023 - 31 December 2023 Coloplast delivered a solid Q1 with 8% organic growth and an EBIT margin 1) of 28%. Reported revenue in DKK grew 8% with 4%-points contribution from Kerecis (underlying growth of around 35%), offset by negative impact from currencies. Organic growth rates by business area: Ostomy Care 8%, Continence Care 8%, Voice and Respiratory Care 7%, Advanced Wound Care 9% (Advanced Wound Dressings 9%) and Interventional...

Today, 24 January 2024, Coloplast Finance B.V. held its Annual General Meeting at which Ernst & Young Accountants LLP was elected as Coloplast Finance B.V.’s auditors. Attachment 02_2024_Change_of_Auditor_Coloplast_Finance_B.V....

On 24 January 2024, Coloplast Finance B.V. held its Annual General Meeting. At the Annual General Meeting, the sole shareholder, Coloplast A/S, approved the annual report for the financial year 2022/23. In addition, Ernst & Young Accountants LLP was appointed as auditor for Coloplast Finance B.V. Attachment 01_2024_Decisions_at_the_Annual_General_Meeting_Coloplast_Finance_B.V....

Hereby please find the Annual Report 2022/23 for the group of Coloplast A/S. Attachment Annual Report 2022-23...

9M 2022/23 Interim financial results, 9M 2022/23 1 October 2022 - 30 June 2023 Coloplast delivered Q3 organic growth of 8% and 28% EBIT margin 1) . Reported revenue in DKK grew 4% to 6,108 million Organic growth rates by business area: Ostomy Care 8%, Continence Care 9%, Voice and Respiratory Care 9%, Wound and Skin Care 4% (Wound Care 5%), and Interventional Urology 7%. Continued good momentum across regions in Chronic Care. China Ostomy Care posted double-digit growth, reflecting a lower...

H1 2022/23 Interim financial results, H1 2022/23 1 October 2022 - 31 March 2023 Coloplast delivered Q2 organic growth of 8% and 28% EBIT margin 1) . Reported revenue in DKK was up by 10%. Organic growth rates by business area: Ostomy Care 6%, Continence Care 6%, Voice and Respiratory Care 9% (2 months), Wound and Skin Care 13% (Wound Care 12%), and Interventional Urology 17%. Solid Q2 for Chronic Care with continued good momentum across regions ex. China, which detracted from growth in Ostomy...

Q1 2022/23 Interim financial results, Q1 2022/23 1 October 2022 – 31 December 2022 Coloplast delivered a solid start to the year with 7% organic growth and a 29% EBIT margin before special items Coloplast delivered 7% organic growth in Q1. Reported revenue in DKK was up by 18%. Organic growth rates by business area: Ostomy Care 8%, Continence Care 7%, Wound and Skin Care 1% (Wound Care -4%), and Interventional Urology 11%. Solid start in Chronic Care, with strong momentum in Ostomy Care across...

Decisions at the Annual General Meeting On 31 January 2023, Coloplast Finance B.V. held its Annual General Meeting. At the Annual General Meeting, the sole shareholder, Coloplast A/S approved the annual report for the financial year 2021/22 (for the first 7-months from incorporation until 30 September 2022). Attachment 01_2023_Annual General Meeting_Coloplast Finance...

Hereby please find the Annual Report 2021/22. Attachment 05_2022_Annual Report 2021-22...

Appointment of Auditors On 4 November 2022, Coloplast Finance B.V. appointed PricewaterhouseCoopers Accountants N.V. as auditors for the company in line with the expectation described in the Base Prospectus dated 9 May 2022 for the notes issued by Coloplast Finance B.V. under the EUR 3,500,000,000 Euro Medium Term Note Program. For further information, please contact Investors and analysts Aleksandra Dimovska Director, Investor Relations Tel. +45 4911 1800 / +45 4911 2458 Email:...

Please see enclosed pdf. For further information, please contact Investors and analysts Anders Lonning-Skovgaard Executive Vice President, CFO Tel. +45 4911 1111 Aleksandra Dimovska Director, Investor Relations Tel. +45 4911 1800 / +45 4911 2458 Email: [email protected] Kristine Husted Munk Sr. Manager, Investor Relations Tel. +45 4911 1800 / +45 4911 3266 Email: [email protected] Press and media Peter Mønster Sr. Media Relations Manager Tel. +45 4911 2623 Email: [email protected]...

On 30 August 2022, Hea Vinskov was elected to the management board in Coloplast Finance B.V. replacing Claus Lundbæk Ottosen. Hea Vinskov is Senior Vice President and Group General Counsel in the Coloplast group. The management board in Coloplast Finance B.V. hereafter consists of: Henrik Deneke, Anton Mikkelsen and Hea Vinskov. Attachment 03_2022 Change in management board...

Coloplast B.V. - Announcement no. 02/2022 - Interim Financial Report, 9M 2021/2022 9M 2021/22 Interim financial results, 9M 2021/22 1 October 2021 - 30 June 2022 Coloplast delivered Q3 organic growth of 8% and an EBIT margin of 30%. Unchanged financial guidance for FY 2021/22, with organic growth at 6-7%, reported growth around 15%, and EBIT margin before special items of around 31% Coloplast delivered 8% organic growth in Q3. Reported revenue in DKK was up by 21%. Organic growth rates by...

DISCLOSURE OF HOME MEMBER STATE BY COLOPLAST FINANCE B.V. NOT INTENDED FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES. NOT INTENDED FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO ANY PERSON IN ANY JURISDICTION WHERE RELEASE, PUBLICATION OR DISTRIBUTION TO SUCH PERSON IS RESTRICTED BY ANY LAW OR REGULATION APPLICABLE IN SUCH JURISDICTION. THIS ANNOUNCEMENT IS NOT AN OFFER TO SELL OR ISSUE OR INVITATION TO PURCHASE OR SUBSCRIBE FOR, OR...